The novel Bruton tyrosine kinase inhibitor ibrutinib and phosphatidyl-4-5-biphosphate 3-kinase-d inhibitor idelalisib are promising drugs for the treatment of chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma, either alone or in combination with anti-CD20 antibodies. We investigated the possible positive or negative impact of these drugs on all known mechanisms of action of both type I and type II anti-CD20 antibodies. Pretreatment with ibrutinib for 1 hour did not increase direct cell death of cell lines or chronic lymphocytic leukemia samples mediated by anti-CD20 antibodies. Pre-treatment with ibrutinib did not inhibit complement activation or complement-mediated lysis. In contrast, ibrutinib strongly inhibited all cell-mediated mechanisms induced by anti-CD20 antibodies rituximab, ofatumumab or obinutuzumab, either in purified systems or whole blood assays. Activation of natural killer cells, and antibody-dependent cellular cytotoxicity by these cells, as well as phagocytosis by macrophages or neutrophils were inhibited by ibrutinib with a half maximal effective concentration of 0.3-3 μM. Analysis of anti-CD20 mediated activation of natural killer cells isolated from patients on continued oral ibrutinib treatment suggested that repeated drug dosing inhibits these cells in vivo. Finally we show that the phosphatidyl-4-5-biphosphate 3-kinase-d inhibitor idelalisib similarly inhibited the immune cell-mediated mechanisms induced by an-
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Ibrutinib interferes with the cell-mediated anti-tumour activities of therapeutic CD20 antibodies: implications for combination therapy
INTRODUCTION
The anti-CD20 antibody rituximab is approved for the treatment of B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL) in combination with chemotherapy. The next generation anti-CD20 monoclonal antibodies, ofatumumab [1] and obinutuzumab (GA101) [2] , were approved more recently and are in clinical trials for the treatment of CLL and BNHL, combined with either standard or novel chemotherapeutic agents. Anti-CD20
antibodies are thought to act through immune mediated mechanisms, in particular complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) by natural killer cells (NK) and antibody-dependent phagocytosis by macrophages [3] ; recent evidence indicates that these monoclonal antibodies can also promote activation of polymorphonuclear neutrophils (PMN) and phagocytosis [4] .
Ofatumumab shows enhanced CDC compared to rituximab whereas obinutuzumab, a glycoengineered anti-CD20, shows more potent ADCC [5, 6] and PMN-mediated phagocytosis [4] . Obinutuzumab also induces significant direct cell death, at least for some cellular targets [6, 7] . Anti-CD20 monoclonal antibodies that mediate substantial CDC, such as rituximab and ofatumumab, are classified as type I, whereas those that induce high homotypic adhesion and direct cell death, such as obinutuzumab, are classified as type II [3] . Despite the advent of next generation anti-CD20 monoclonal antibodies, these drugs are likely to perform best when combined with chemotherapeutic agents that employ different or synergistic mechanisms of action. Rituximab is most often combined with CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone) and with fludarabine and/or cyclophosphamide. The known role of B-cell receptor (BCR) signaling in the pathogenesis of B-cell neoplasms has led to the investigation of several specific kinase inhibitors as potential novel drugs for these diseases [8] [9] [10] . The most studied are the Bruton tyrosine kinase (Btk) inhibitor ibrutinib, the phospatidyl-4-5-biphosphate-3 (PI3)-kinase-d inhibitor idelalisib (CAL-101), the Syk inhibitors fostamatinib and GS-9973 and the pan-kinase inhibitor dasatinib [8, 10, 11] . Ibrutinib has recently been approved as a single agent for the treatment of refractory and relapsed CLL and mantle cell lymphoma, and combinations of ibrutinib with other drugs, including anti-CD20 antibodies, are currently being tested in phase 2-3 clinical trials in the same diseases (www.clinicaltrials.gov) [12] [13] [14] [15] [16] [17] . The molecular target of ibrutinib, Btk, is a Tec family tyrosine kinase that regulates signaling downstream of the BCR and other immuno-receptors, including Tolllike and chemokine receptors. BCR plays a major role in B-cell development and differentiation and is deleted or mutated in X-linked agammaglobulinemia [8, 18] . Idelalisib is another kinase inhibitor in advanced clinical development [19, 20] . Results of a phase 3 study in relapsed CLL patients has shown a significant therapeutic advantage of rituximab in combination with idelalisib, compared to rituximab alone [19] . In view of the use of CD20 monoclonal antibodies in combination with novel kinase inhibitors in the clinic, we investigated the effect of ibrutinib and idelalisib on all known mechanisms of action of type I and II anti-CD20 monoclonal antibodies, including direct cell death, CDC, ADCC and phagocytosis by macrophages and PMN. 
MATERIAL AND METHODS

Target cells and patients
Cell growth and cytotoxicity assays
For cytotoxicity assays with the Alamar blue dye, 5x10 3 cells from lymphoma cell lines were incubated for 48 h with ibrutinib and/or 10 µg/mL anti-CD20 antibodies.
A one-tenth volume of Alamar blue was then added and the incubation continued overnight. Fluorescence was read in a plate reader (FluoroStar Optima, BMG) [21] . Cell growth and death induction were measured by flow cytometry after plating lymphoma cell lines at 3x10 4 cells/well. Percentages and absolute counts of live and dead cells were measured by 7-aminoactinomycin (7-AAD) staining (BD Biosciences) and flow cytometry using calibration beads (Bright Count Microspheres, IQ Products, Groningen, the Netherlands).
Complement activation and cytotoxicity
Cell lines were pre-treated for 1 h with kinase inhibitors. Anti-CD20 or control monoclonal antibodies were then added (no wash) and, 10 min later, 20% pooled human serum. After incubation for 4 h at 37°C, cells were stained with 7-AAD and cell death was analyzed by flow cytometry (FACSCanto II, BD Biosciences). For measurement of CDC in CLL cells, whole blood assays were performed [7, 22] . Briefly peripheral blood from normal donors or patients with CLL was drawn into 50 μg/mL lepirudin [23] . Kinase inhibitors were added, followed 1 h later by anti-CD20-opsonized CLL. Complement activation was measured after 1 h by staining with FITC-labeled anti-C3b/iC3b/C3d monoclonal antibody 1H8 [24] . Cytotoxicity was assessed after 
Phagocytosis by macrophages
Monocyte-derived macrophages were generated as described elsewhere [25] and pre-treated for 1 h with kinase inhibitors before adding targets. CLL cells were stained with 0.1 μM carboxyfluorescein succinimidyl ester (Molecular Probes, Thermo Scientific Inc., USA) and incubated with the macrophages in the presence or absence of anti-CD20 or control monoclonal antibodies. After 2 h of incubation at 37°C, cells were harvested and stained with anti-CD19-APC and anti-CD11b-PE (both from BD Biosciences) and analyzed by flow cytometry [7] .
Statistical analysis
The data were analyzed using paired or unpaired Student's t-test, or a one-way ANOVA as appropriate.
RESULTS
Ibrutinib does not enhance direct cell death induced by anti-CD20 antibodies
We first investigated the effect of ibrutinib alone on B-cell lymphoma and CLL cell lines using Alamar blue vital dye. Treatment for 72 h with 1-10 μM ibrutinib showed that the BJAB cell line was more sensitive than MEC-1, with about 10% versus 40-50% viable cells, respectively, at concentrations of 3-10 μM ibrutinib ( Figure 1A) . The IC50 was about 1 μM for BJAB and 3 μM for MEC-1.
Experiments in which we washed away the kinase inhibitor after different periods of exposure showed that a 2 h exposure is sufficient to obtain a full inhibitory effect (data not shown). Since a decrease in viable cells in growing cell lines may be due to either inhibition of proliferation or induction of cell death, flow cytometry experiments were also performed using 7-AAD staining and calibration beads. Analysis of absolute number of live cells at different time points showed that ibrutinib inhibits proliferation of both BJAB and MEC-1 at a concentration of 1-10 μM (Online Supplementary Fig- ure S1). However the drug is significantly cytotoxic only for BJAB at the same drug doses ( Figure 1B) . The type II anti-CD20 antibody obinutuzumab has been reported to induce direct cell death of some cell lines [26, 27] . We therefore investigated whether ibrutinib may synergize with anti-CD20 antibodies. We observed in Alamar blue assays that the MEC-1 cell line responded to obinutuzumab with a 30% decreased number of live cells at 48 h compared to control ( Figure 1C ). Pre-treatment for 1 h with 0.1-10 μM ibrutinib before adding obinutuzumab did not further increase, and if anything reduced, the effect of obinutuzumab ( Figure   1C ). BJAB or CLL samples did not respond to obinutuzumab or the other anti-CD20 antibodies alone, as investigated by a reduction of live cells after 48-72 h of treatment, as previously reported [7] , and addition of ibrutinib did not modify this ( Figure 1D and data not shown). We conclude that ibrutinib does not have additive or synergistic effects with anti-CD20 monoclonal antibodies in terms of inhibition of proliferation and/ or direct cell death induction. act entirely through CDC [22] . Whole blood from healthy normal donors was pretreated with ibrutinib for 1 h, after which CLL cells opsonized with 3 μg/mL ofatumumab were added and the mixture incubated overnight at 37°C. Ofatumumab-mediated CDC was not affected by ibrutinib at a concentration up to 10 μM ( Figure 2B ). Similar results were obtained using whole blood from CLL patients ( Figure 2C ). In agreement with these results, C3 complement fragment deposition on CLL cells in whole blood was not affected by 1 h pretreatment with ibrutinib ( Figure 2D ). We also measured whether exposure to ibrutinib for 24-72 h modulated expression of CD20 or the complement inhibitors CD55 and CD59 and found that 1-10 μM ibrutinib did not significantly modulate expression of any of these molecules in either DOHH-2 or MEC-1 cell lines (data not shown). We conclude that ibrutinib has no significant effect on CDC induced by anti-CD20 antibodies.
Ibrutinib inhibits natural kill cell activation and antibody dependent cellular cytotoxicity in vitro and in vivo
We next investigated the effect of ibrutinib on NK-cell degranulation and ADCC mediated by anti-CD20 monoclonal antibodies, a major mechanism of these antibodies [6, 28] . The negative control was irrelevant trastuzumab antibody. When peripheral blood mononuclear cells were co-cultured with CLL cells opsonized with the different anti-CD20 monoclonal antibodies, glycoengineered obinutuzumab induced a stronger degranulation of NK cells than did rituximab or ofatumumab, as expected [7] .
One hour pre-treatment of peripheral blood capacity of the NK cells from these samples to degranulate in response to anti-CD20 opsonized BJAB cells was then measured.
As shown in Figure 4A Figure 4B ). Collectively, these data suggest that NK cells are inhibited in vivo after ibrutinib administration.
Ibrutinib inhibits phagocytosis by macrophages and polymorphonuclear neutrophils
We next investigated the effect of ibrutinib on antibody dependent phagocytosis.
Phagocytosis of CLL targets opsonized with 1 μg/mL rituximab, ofatumumab or obinutuzumab by macrophages differentiated in vitro was measured by flow cytometry [22] . Figure 5A ).
Anti-CD20 opsonized targets also mediate activation of PMN and phagocytosis [4] . We therefore analyzed the effect of ibrutinib on these mechanisms. Both PMN activation by obinutuzumab-opsonized CLL targets and phagocytosis of the same targets in whole blood was inhibited by 1 h of pre-treatment with ibrutinib, with an EC50 of about 1 μM ( Figure 5B, 5C ). We conclude that ibrutinib interferes with several cell mediated mechanisms of anti-CD20 antibodies: ADCC, phagocytosis by macrophages, activation and phagocytosis by PMN.
Comparison with idelalisib
The PI3K-d inhibitor idelalisib also acts downstream of the BCR [8, [18] [19] [20] . We, therefore, investigated whether the observed inhibition of cell-mediated effector mechanisms could also be seen with idelalisib.
All the above anti-CD20 antibody effector mechanisms were investigated, using 10 μM ibrutinib or idelalisib. Pretreatment with idelalisib for 1 h did not affect CDC in CLL whole blood assays. Indeed the cell Figure   S3 ). Furthermore, obinutuzumab-dependent PMN activation was less strongly inhibited by idelalisib (27% inhibition) than ibrutinib (60% inhibition) ( Figure 6D, P<0 .01). The same was true for ofatumumab-induced macrophage-mediated phagocytosis, although the difference in inhibition between the two agents was not statistically significant (50% versus 63% inhibition, respectively, Figure 6E ). within the tumor microenvironment [9, 29] . Different mutations in Btk or in downstream signaling effector molecules in neoplastic B cells, as well as B-cell anergy, may determine sensitivity in vitro and in vivo [21, 22, 32, 33] . Complement activation and CDC were not significantly affected by ibrutinib after 1-h pre-exposure to the kinase inhibitor. Longer periods of exposure to ibrutinib (72 h) did not significantly modify expression of CD20 or the complement inhibitors CD55 and CD59 (data not shown), suggesting that altogether ibrutinib has little effect on CDC. A recently published report describes that ibrutinib down-modulates CD20 protein expression and gene transcription in some cell lines (e.g. Raji) and CLL samples, and that this leads to inhibition of CDC [34] . The difference with our data may be due to the different cell lines tested, since these authors showed no modulation of CD20 by ibrutinib in MEC-1, in agreement with our findings. In the context of complement, it is worth noting that ibrutinib and other kinase inhibitors acting downstream of the BCR induce early lymphocytosis in vivo due to egress of neoplastic B cells into the peripheral blood [35] [36] [37] . This property may be an advantage for subsequent CDC induction by co-administered anti-CD20 monoclonal antibodies, since complement is abundant and fully active in the periphery [22] . The efficacy of CDC may, however, be reduced by the potential down modulation of CD20 and up-regulation of CD55 after prolonged exposure to ibrutinib, at least in some cases [34] . ADCC is thought to be a major effector mechanism of anti-CD20 monoclonal antibodies [28] , especially for glycoengineered obinutuzumab which binds FcγRIIIA more efficiently [6] . We showed here that ibrutinib strongly inhibited Our findings are in agreement with and extend recently published data that showed inhibition of antibody-induced NK-cell degranulation, NK-cell-mediated cytokine production and ADCC by 0.1-1 μM ibrutinib [34, 38] . A direct role of Btk in NK cell activation and cytotoxicity has emerged from work with Btk knock-out mice as well FIGURE 6 Idelalisib (IDE) also inhibits cell-mediated activities of CD20 monoclonal antibodies (mAb), but more weakly than ibrutinib (IBR).
DISCUSSION
The following immune-mediated mechanisms of anti-CD20 monoclonal antibodies were studied in the absence or presence of 10 μM IBRU or 10 μM IDE: (A) Ofatumumab (OFA)-dependent CDC of CLL cells in normal donor whole blood, (B) NK-cell degranulation in peripheral blood mononuclear cells induced by obinutuzumab (OBZ)opsonized CLL cells, (C) OFA-and OBZ-dependent ADCC of the MEC-1 cell line, (D) PMN activation in whole blood in response to OBZ-opsonized CLL and (E) phagocytosis by macrophages of OFA-opsonized CLL. All results are the means and standard deviations for three independent experiments. *P<0.05; **P<0.01; ***P<0.001. as in patients with X-linked agammaglobulinemia [39] . In the latter study, however, TLR3 rather than FcγR-mediated signaling was investigated. Interestingly ibrutinib has also been shown recently to inhibit Itk, another Tec family kinase like Btk [40] . Itk is predominantly expressed by T cells and signals downstream of the T-cell receptor [41] and has been reported to be required for the activation of human NK cells through FcγRIII [42] . Thus ibrutinib may inhibit NK cells through either Btk or Itk, or both. A recent study using the Itk-specific inhibitor CGI-1746 suggests that Itk in NK cells is an important signaling molecule to mediate ADCC [38] . Finally ibrutinib is not fully specific for Btk, so other kinases, such as Tec, Blk and Bmx, may be involved in the effects of the drug in B cells as well as immune effector cells described here, especially at the highest 10 μM dose [43] .
However, the precise definition of the kinases involved in each case is beyond the scope of this article. We were also able to study the degranulation capacity of NK cells isolated from patients with B-NHL treated with oral ibrutinib 560 mg/die. We found a significantly decreased capacity of NK cells to degranulate after a single oral dose of ibrutinib in three patients. Furthermore in one patient who could be analyzed after 3 weeks of continuous treatment, NK cells were even more markedly inhibited with respect to pre-treatment cells. Published pharmacokinetic data suggest that peak concentrations of ibrutinib of approximately 0.25 μM (100 ng/mL), an effective concentration to inhibit ADCC in vitro, may be reached 2 h after a single 560 mg administration in vivo [12] . Furthermore Dubosvky et al. also demonstrated ibrutinib binding to Itk in vivo after eight daily oral administrations of the drug [40] . Together these data suggest that repeated treatment with ibrutinib may lead to inhibition of NK-cell-mediated mechanisms induced by antiCD20 monoclonal antibodies in vivo.
Analysis of anti-CD20 monoclonal antibody-mediated phagocytosis by macrophages and PMN showed that ibrutinib also strongly inhibited these reactions. These data are in agreement with studies showing that Btk is expressed by myeloid lineage cells and is involved in the activation, cytokine production and chemotaxis of macrophages, granulocytes and mast cells [44] [45] [46] . The EC50 for this inhibition was in the range of 0.3 to 3 μM. It is possible that these processes may be inhibited by standard ibrutinib dosing in vivo, although this was not directly demonstrated here. This is particularly important since phagocytosis and myeloid cells have been implicated as major players in the therapeutic activity of anti-CD20 and other monoclonal antibodies in vivo [4, [47] [48] [49] [50] .
Finally, we compared the inhibitory effects in vitro of the PKI3-d inhibitor idelalisib with those of ibrutinib. We observed that idelalisib had similar inhibitory effects as ibrutinib on CDC, NK cell degranulation, ADCC, PMN activation and macrophage phagocytosis, but at lower levels when used at an equal 10 μM dose. These data suggest that these properties may be common to several kinase inhibitors acting downstream of the BCR [8, 18] , although the observed differences in potency may lead to different consequences in vivo and need to be more fully investigated. The data presented here underline the multiple negative interactions between ibrutinib and anti-CD20 monoclonal antibodies and have important implications for the design of schedules for combined therapy. Indeed concurrent rituximab plus ibrutinib therapy in mouse models appears to lead to worse outcome compared to sequential drug schedules (whichever the order) [38] . The data presented here suggest that the reason for these observations may be ascribed to inhibition not only of NK cell-mediated mechanisms, as previously reported, but also macrophage-and/or PMN-mediated mechanisms triggered by anti-CD20 monoclonal antibodies. Thus, although initial clinical data suggest a favorable response of patients to ibrutinib or idelalisib in combination with rituximab [17, 19] , modification of dosing schedules may be designed to exploit the effector mecha- Timing of ibrutinib dosing might, therefore, be less critical when combined with anti-CD20 monoclonal antibodies with strong CDC capacity. Finally, anti-CD20 monoclonal antibodies may also be usefully given as a maintenance therapy after cessation of the kinase inhibitor. In this case, however, the timing of the recovery of full cell-mediated effector functions will need to be more precisely investigated.
Indeed we propose that several of the markers investigated here (NK-cell degranulation and PMN activation capacity) may be used in the future to better define the immune function of blood cells isolated from patients at various stages of kinase inhibitor treatment and to design appropriate and optimal drug schedules.
